A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

被引：0
|
作者：
Nazha, Aziz [1 ]
Kantarjian, Hagop [1 ]
Borthakur, Gautam [1 ]
Kadia, Tapan M. [1 ]
Faderl, Stefan [1 ]
Ravandi, Farhad [1 ]
Estrov, Zeev [1 ]
Jabbour, Elias [1 ]
Quintas-Cardama, Alfonso [1 ]
Cortes, Jorge E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6589
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
    Erba, Harry P.
    Oluwole, Olalekan O.
    Bixby, Dale
    Rampal, Raajit K.
    Fathi, Amir T.
    Paliwal, Prashni
    Jin, Jin
    Inoue, Ai
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S311 - S312
  • [12] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [13] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [14] Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Cortes, Jorge E.
    Faderl, Stefan
    Pagel, John
    Jung, Chul Won
    Yoon, Sung-Soo
    Koh, Youngil
    Pardanani, Animesh Dev
    Hauptschein, Robert S.
    Lee, Kyoung-June
    Lee, Je-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [15] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [16] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [17] A Phase I/II Study of Venetoclax in Combination with 5Azacytidine in Treatment-Naive and Relapsed/Refractory HighRisk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Bazinet, Alexandre
    Jabbour, Elias J.
    Kantarjian, Hagop
    Chien, Kelly S.
    DiNardo, Courtney D.
    Ohanian, Maro
    Daver, Naval
    Kanagal-Shamanna, Rashmi
    Kadia, Tapan M.
    Takahashi, Koichi
    Masarova, Lucia
    Short, Nicholas J.
    Alvarado, Yesid
    Thompson, Philip A.
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Ravandi, Farhad
    Kornblau, Steven M.
    Pemmaraju, Naveen
    Schneider, Heather
    Mirabella, Bailey
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [18] Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Blum, William
    Klisovic, Rebecca B.
    Walker, Alison
    Garzon, Ramiro
    Liu, Shujun
    Schaaf, Larry J.
    Humphries, Kristina
    Grever, Michael R.
    Devine, Steven M.
    Byrd, John C.
    Marcucci, Guido
    BLOOD, 2009, 114 (22) : 815 - 816
  • [19] Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
    Qi, Junyuan
    Wei, Xudong
    Li, Qiubai
    Chang, Chukang
    Zhou, Fuling
    Huang, Jianying
    Zhang, Yu
    Xu, Chongyuan
    Tang, Xiaowen
    Jiang, Qian
    Li, Junmin
    Qin, Qun
    He, Qun
    Gao, Sujun
    Liu, Liping
    Chen, Zi
    Yu, Min
    Wang, Jing
    Men, Lichuang
    Wang, Hengbang
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [20] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
12345